What does CJC-1295 without DAC (Mod GRF 1-29) stack well with?

For body composition / training protocols, CJC-1295 without DAC (Mod GRF 1-29) pairs with compounds on complementary pathways: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500. These pairings are selected because they engage independent receptor systems from CJC-1295 without DAC (Mod GRF 1-29)'s primary mechanism (Same GHRH-receptor agonism as DAC variant), producing additive or synergistic effects rather than receptor competition.

What is the regulatory status of CJC-1295 without DAC (Mod GRF 1-29)?

CJC-1295 without DAC (Mod GRF 1-29) regulatory status: Unapproved in the United States; WADA status banned (s2 class); research level mechanistic studies; off-label use widespread. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For anabolic and recovery use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What is the evidence base for CJC-1295 without DAC (Mod GRF 1-29)?

CJC-1295 without DAC (Mod GRF 1-29)'s evidence base sits at mechanistic studies; off-label use widespread. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The body composition / training interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Is CJC-1295 without DAC (Mod GRF 1-29) safe during pregnancy or breastfeeding?

CJC-1295 without DAC (Mod GRF 1-29), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Will CJC-1295 without DAC (Mod GRF 1-29) actually increase lean mass?

CJC-1295 without DAC (Mod GRF 1-29)'s effect on body composition depends on which dimension of the anabolic cascade it engages. Direct GH/IGF-axis engagement supports lean mass through protein synthesis and satellite cell activation. Effect size is proportional to training stimulus and nutritional adequacy.

Home/ Compounds/ CJC-1295 without DAC (Mod GRF 1-29)

CJC-1295 without DAC (Mod GRF 1-29)

Body Composition

For the body-composition and physique community, CJC-1295 without DAC (Mod GRF 1-29) is run inside a training-driven framework where the compound supports rather than substitutes for stimulus and nutrition. Same GHRH-receptor agonism as DAC variant Four amino acid substitutions resist enzymatic cleavage. Without the albumin-binding tail, the molecule clears in roughly half an hour — useful for evening dosing that mimics natural sleep-time GH pulse.. The ~30 min pharmacokinetic profile determines training-day versus rest-day dosing, while the subq administration shapes injection-site rotation and protocol planning.

Body Composition / Training Applications

Injury RecoveryRecoveryBody RecompositionTendon RepairWorkout Recovery

Key Takeaways

Body composition lens: response to CJC-1295 without DAC (Mod GRF 1-29) is proportional to training stimulus and nutritional adequacy.
Mechanism: Same GHRH-receptor agonism as DAC variant.
Body composition dose: 100 mcg 1-3x daily subq via subq; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

For trained users, CJC-1295 without DAC (Mod GRF 1-29)'s body composition response is generated at the intersection of compound pharmacology, training stimulus, and nutritional input. Same GHRH-receptor agonism as DAC variant. Four amino acid substitutions resist enzymatic cleavage. Without the albumin-binding tail, the molecule clears in roughly half an hour — useful for evening dosing that mimics natural sleep-time GH pulse. The mechanism informs which training and nutrition pattern maximises the response; the subsections below work through this for the four dimensions tracked in body composition protocols.

Recovery window and training frequency

The most reliably reported effect of CJC-1295 without DAC (Mod GRF 1-29) in athlete populations is on the recovery window between sessions. Faster connective tissue recovery, better sleep quality, and reduced systemic inflammation translate into more high-quality training days per cycle. This is the practical mechanism by which body composition shifts for most users — not via dramatic acute anabolic effect but via more accumulated quality training.

Hyperplasia and structural adaptation

Where CJC-1295 without DAC (Mod GRF 1-29) demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Anabolic substrate and protein synthesis

CJC-1295 without DAC (Mod GRF 1-29)'s relevance to body composition depends on where in the anabolic cascade it acts. It engages the GH/IGF-1 axis directly, with measurable effects on protein synthesis, satellite cell activation, and lean mass over a typical 8–12 week cycle. The downstream effect on body composition is dose- and training-dependent.

Body Composition / Training Applications

Recovery

For recovery, CJC-1295 without DAC (Mod GRF 1-29) integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Strength

Strength responds to CJC-1295 without DAC (Mod GRF 1-29) with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Lean Mass

The body composition community converges on CJC-1295 without DAC (Mod GRF 1-29) for lean mass with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Cardiovascular Conditioning

For cardiovascular conditioning, CJC-1295 without DAC (Mod GRF 1-29) integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60 mcg	4–6 weeks initial cycle
Body Composition focus	SubQ	100 mcg	1-3x daily SubQ
Maintenance phase	SubQ	70 mcg	Ongoing with periodic pauses

Dose timing for CJC-1295 without DAC (Mod GRF 1-29) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

CJC-1295 without DAC (Mod GRF 1-29) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

CJC-1295 without DAC (Mod GRF 1-29) + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in body composition / training protocols.
CJC-1295 without DAC (Mod GRF 1-29) + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in body composition / training protocols.
CJC-1295 without DAC (Mod GRF 1-29) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in body composition / training protocols.
CJC-1295 without DAC (Mod GRF 1-29) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Banned (S2 class) FDA: Unapproved Research: Mechanistic studies; off-label use widespread

Short half-life produces fewer sustained-IGF-1 concerns than DAC variant. Site reactions common. Stack with ipamorelin for synergy.

Lens-specific safety considerations for body composition / training use of CJC-1295 without DAC (Mod GRF 1-29): Short half-life produces fewer sustained-IGF-1 concerns than DAC variant. Site reactions common. Stack with ipamorelin for synergy. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

CJC-1295 sustained GH release

PMID 16940290

Supporting

Tetra-substituted GHRH analogues

PMID 17684183

CJC-1295 without DAC (Mod GRF 1-29) vs Related Peptides

Compound	Profile	Onset	Best For
CJC-1295 without DAC (Mod GRF 1-29)	Short-acting GHRH analogue	~30 min	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

How does CJC-1295 without DAC (Mod GRF 1-29) compare to AAS for body composition?

Peptide therapeutics including CJC-1295 without DAC (Mod GRF 1-29) produce more modest body composition shifts than anabolic-androgenic steroids and operate on different mechanisms with substantially different side-effect profiles. The compound is most-appropriate for users prioritising long-term sustainability and clean blood work over maximum acute mass.

Training-day only or daily dosing?

For most peptide compounds with short-to-moderate half-life, training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The choice depends on the user's training volume and the compound's pharmacokinetics. Daily dosing for 4-7 days is the default; training-day-only protocols are appropriate for lower-volume programmes.

Should I cycle CJC-1295 without DAC (Mod GRF 1-29)?

Standard cycle structure for body composition use is 8–12 weeks on, 4 weeks off. Continuous indefinite use is not advised for most compounds in this class; the off-period preserves dose response and reduces cumulative downregulation. Cycle stacking with complementary peptides is common in advanced protocols.

Will CJC-1295 without DAC (Mod GRF 1-29) affect my training performance?

Most commonly via faster recovery between sessions, which permits higher training frequency and intensity. Acute performance-enhancing effects in a single session are not the typical profile. Users typically need to upregulate nutrition and adjust programming to take advantage of the increased recovery capacity.

What should I look for in CJC-1295 without DAC (Mod GRF 1-29) sourcing and quality?

Acceptable CJC-1295 without DAC (Mod GRF 1-29) certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching ~3367 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How should CJC-1295 without DAC (Mod GRF 1-29) be stored and reconstituted?

Lyophilised CJC-1295 without DAC (Mod GRF 1-29) stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Clinical Protocol

Start a CJC-1295 without DAC (Mod GRF 1-29) Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified CJC-1295 without DAC (Mod GRF 1-29) and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: ~3367 Da
Sequence length: 29 aa
Half-life: ~30 min
WADA: Banned (S2 class)
FDA: Unapproved
Research: Mechanistic studies; off-label use widespread

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 without DAC (Mod GRF 1-29) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for CJC-1295 without DAC (Mod GRF 1-29)

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised